Understanding bile duct cancer, molecular profiling, targeted therapies, immunotherapy, surgery, clinical trials, supportive care, and practical resources — organized by where you are in the journey.
This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature and clinical trial records. Every important decision must be made together with the patient’s medical team — hepatobiliary surgeons, medical oncologists, interventional radiologists, and gastroenterologists. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. Trouvera’s guides are produced using AI-assisted research synthesis with human editorial review; it is not written by treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. Every option discussed in this guide is intended as an addition to, not a replacement for, evidence-based standard treatments delivered by a qualified hepatobiliary oncology team. Cholangiocarcinoma treatment requires specialized multidisciplinary care at a center experienced in biliary tract cancers.
Biliary obstruction is a medical urgency. If you develop yellowing of the skin or eyes (jaundice), dark urine, pale stools, itching, or fever with chills, contact your medical team immediately. Biliary obstruction and cholangitis (bile duct infection) require urgent drainage procedures.
Content last reviewed: June 2026 · Based on NCCN Biliary Tract Cancers v2.2026, ESMO Clinical Practice Guidelines for Biliary Tract Cancers, ASCO Guidelines, TOPAZ-1, KEYNOTE-966, FIGHT-202, ClarIDHy, FOENIX-CCA2, ReFocus trials, eNRGy (zenocutuzumab), and published medical literature · Always verify trial availability and treatment details with your medical team and primary sources.
⚡ Quick Start — If You Read Nothing Else
The 8 most important things to know right now.
Get molecular profiling (NGS) on your tumor tissue immediately. Approximately 40–50% of cholangiocarcinomas harbor actionable mutations (FGFR2, IDH1, HER2, BRAF, NTRK, NRG1, MSI-H) that have FDA-approved targeted therapies. Without this testing, you may miss treatments that could significantly help you.
Durvalumab + gemcitabine/cisplatin is the new standard first-line treatment. The TOPAZ-1 trial showed that adding the immunotherapy drug durvalumab to standard chemotherapy improved survival. This is now the recommended first-line regimen for most patients with advanced cholangiocarcinoma.
If your tumor has an FGFR2 fusion or rearrangement, FDA-approved drugs exist. Pemigatinib (Pemazyre), futibatinib (Lytgobi), and other FGFR inhibitors are available. These are most common in intrahepatic cholangiocarcinoma (~10–20% of cases).
Surgery is the only potentially curative treatment, but only ~35% of patients are candidates. If your tumor can be completely removed, surgery offers the best chance of long-term survival. Seek evaluation at a high-volume hepatobiliary center.
Cholangiocarcinoma has three distinct subtypes with different biology. Intrahepatic (within the liver), perihilar/Klatskin (at the junction of bile ducts), and distal (near the small intestine). Treatment approaches differ by subtype.
Biliary drainage is critical and sometimes urgent. Many patients present with blocked bile ducts causing jaundice. Drainage (stenting) must be addressed before or during cancer treatment.
Clinical trials are essential. Cholangiocarcinoma is relatively rare, and the treatment landscape is evolving rapidly. Trials offer access to promising new therapies. Ask about trials at every visit.
Get to a specialized hepatobiliary center. Cholangiocarcinoma requires expertise from hepatobiliary surgeons, medical oncologists, interventional radiologists, and gastroenterologists working as a team. Multidisciplinary tumor board review is essential.
▼ Collapse
Understanding Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a cancer that arises from the cells lining the bile ducts — the tubes that carry bile from the liver to the small intestine. Bile is a fluid made by the liver that helps digest fats. CCA is part of a broader group called biliary tract cancers, which also includes gallbladder cancer and ampullary cancer.
CCA is considered a rare cancer, but its incidence is rising worldwide, particularly the intrahepatic subtype. In the United States, approximately 8,000 new cases are diagnosed each year. The reasons for this increase are not fully understood but may relate to improved diagnostic imaging, rising rates of metabolic liver diseases, and increased recognition of intrahepatic tumors.
CCA is often diagnosed at an advanced stage because early symptoms are vague or absent. When caught early enough for surgery, long-term survival is possible. When diagnosed at a later stage, newer treatments — particularly immunotherapy combinations and targeted therapies — are extending lives and improving quality of life more than at any previous time.
Intrahepatic cholangiocarcinoma (iCCA): Arises within the liver. Accounts for approximately 10–20% of all primary liver cancers. Most commonly presents as a liver mass. More likely to harbor FGFR2 fusions and IDH1 mutations. Rising incidence.
Perihilar cholangiocarcinoma (pCCA), also called Klatskin tumor: Arises at or near the junction where the right and left hepatic ducts merge. The most common subtype (~50–60% of CCA). Typically presents with jaundice. Named after Dr. Gerald Klatskin, who characterized it in 1965.
Distal cholangiocarcinoma (dCCA): Arises in the portion of the common bile duct that passes through the pancreas and connects to the small intestine. Accounts for approximately 20–30% of CCA. Often presents with obstructive jaundice.
These three subtypes have different risk factors, molecular profiles, surgical approaches, and sometimes different responses to systemic treatment. This is why knowing your exact subtype matters.
Primary sclerosing cholangitis (PSC): A chronic inflammatory condition of the bile ducts, often associated with ulcerative colitis. The strongest known risk factor in Western countries. Lifetime CCA risk approximately 5–10%.
Liver fluke infection: Particularly Opisthorchis viverrini and Clonorchis sinensis, prevalent in Southeast Asia (Thailand, Laos, Cambodia, Vietnam, China). A major reason CCA rates are much higher in these regions.
Bile duct cysts (choledochal cysts) and Caroli disease: Congenital abnormalities of the bile ducts that increase CCA risk.
Hepatolithiasis: Stones within the bile ducts inside the liver. More common in East Asia.
Chronic liver disease and cirrhosis: Hepatitis B, hepatitis C, alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD/MASLD) all increase intrahepatic CCA risk.
Thorotrast exposure: A historical contrast agent used in radiology (discontinued in the 1950s). Decades-later CCA risk.
No identifiable risk factor: The majority of CCA cases in Western countries occur without any known risk factor.
The most important concept in this guide: Cholangiocarcinoma treatment in 2026 is driven by molecular profiling. Approximately 40–50% of tumors harbor actionable mutations with FDA-approved targeted therapies. Insist on comprehensive genomic profiling (NGS) on your tumor tissue at diagnosis. If your initial biopsy is insufficient for NGS, discuss options for re-biopsy or liquid biopsy (ctDNA) with your oncologist.
Newly Approved in 2026:FDA-APPROVED In May 2026 the FDA approved a new targeted drug, zenocutuzumab-zbco (Bizengri), for a rare subset of bile duct cancers that carry a specific genetic change called an NRG1 (neuregulin-1) gene fusion. It is intended for patients whose cancer has grown after earlier (prior systemic) treatment, and it is given as an antibody (an infusion that targets the HER2 and HER3 proteins on cancer cells). This is the first targeted therapy approved for NRG1-fusion bile duct cancer, based on the eNRGy trial. Importantly, it only applies to tumors with a confirmed NRG1 fusion — which is one more reason that molecular (genomic) testing of your tumor matters, because these fusions are usually found only with comprehensive, RNA-based sequencing.
Key Breakthroughs in Cholangiocarcinoma
The treatment landscape for CCA has changed more in the past 5 years than in the previous 30. Here are the most important advances:
FDA-APPROVED The TOPAZ-1 trial established durvalumab (an anti-PD-L1 immunotherapy) plus gemcitabine and cisplatin as the new standard first-line treatment for advanced biliary tract cancers, including cholangiocarcinoma. This combination improved overall survival compared to chemotherapy alone (median OS 12.8 vs. 11.5 months; 2-year OS 24.9% vs. 10.4%). The benefit was durable — a subset of patients had prolonged responses lasting years. FDA-approved September 2022.
FDA-APPROVED The KEYNOTE-966 trial showed that pembrolizumab (an anti-PD-1 immunotherapy) plus gemcitabine and cisplatin also improved overall survival compared to chemotherapy alone in advanced biliary tract cancers (median OS 12.7 vs. 10.9 months). This provides an alternative immunotherapy-chemotherapy combination for first-line treatment.
FDA-APPROVED FGFR2 fusions and rearrangements are found in approximately 10–15% of intrahepatic CCA. Multiple FGFR inhibitors are now FDA-approved:
Pemigatinib (Pemazyre): First FGFR inhibitor approved for CCA (April 2020). Accelerated approval for previously treated CCA with FGFR2 fusions/rearrangements based on the FIGHT-202 trial (ORR 36%, median DOR 9.1 months).
Futibatinib (Lytgobi): An irreversible FGFR inhibitor approved September 2022. Based on the FOENIX-CCA2 trial (ORR 42%, median DOR 9.7 months). May retain activity against some resistance mutations that develop on other FGFR inhibitors.
Infigratinib (Truseltiq): FDA-approved May 2021 but later voluntarily withdrawn from the US market in 2024 by the manufacturer for commercial reasons, not safety or efficacy concerns. May still be available outside the US.
FDA-APPROVED Ivosidenib is an IDH1 inhibitor approved for previously treated IDH1-mutated CCA based on the ClarIDHy trial. IDH1 mutations are found in approximately 13–20% of intrahepatic CCA. The ClarIDHy trial showed ivosidenib improved progression-free survival (median PFS 2.7 vs. 1.4 months) and overall survival (median OS 10.8 vs. 9.7 months, adjusted for crossover). While the numbers may seem modest, many patients experienced prolonged disease stabilization and maintained quality of life.
FDA-APPROVED Zanidatamab (Ziihera, Jazz/Zymeworks) is a bispecific HER2-directed antibody approved in November 2024 for previously treated HER2-positive (IHC 3+) biliary tract cancers. Based on the HERIZON-BTC-01 trial, zanidatamab achieved an objective response rate of approximately 41% in HER2-positive (IHC 3+) BTC. HER2 positivity (IHC 3+) is found in approximately 5–15% of biliary tract cancers (more common in gallbladder cancer and extrahepatic CCA).
Comprehensive next-generation sequencing (NGS) has transformed CCA from a single disease treated with one chemotherapy regimen to a collection of molecularly distinct cancers, many with specific targeted therapies. An estimated 40–50% of CCA tumors have at least one actionable genetic alteration. Without NGS, these patients would miss potentially life-extending treatments. Testing should be performed at diagnosis, and if tissue is insufficient, liquid biopsy (circulating tumor DNA, ctDNA) is an acceptable alternative.
Diagnosis: The Tests You Need
CCA diagnosis requires a combination of imaging, tissue sampling, and laboratory tests. The workup is complex because bile duct tumors can be difficult to access and can mimic other conditions.
Liver function tests: Bilirubin (often elevated with biliary obstruction), alkaline phosphatase (ALP), GGT, ALT, AST. These help assess bile duct function and liver health.
Tumor markers: CA 19-9 is the most commonly used marker. Elevated in approximately 50–70% of CCA patients. Not specific to CCA (can be elevated in pancreatitis, other cancers, and in patients with Lewis antigen-negative blood type). CEA may also be checked.
Complete blood count and coagulation: Prolonged obstruction can cause vitamin K malabsorption and coagulopathy.
CT scan (contrast-enhanced, multiphasic): The initial imaging study for most patients. Can identify the tumor location, size, vascular involvement, lymph nodes, and distant metastases.
MRI with MRCP (magnetic resonance cholangiopancreatography): Provides detailed images of the bile ducts and is particularly useful for perihilar tumors. MRCP is a non-invasive way to map the biliary tree.
ERCP (endoscopic retrograde cholangiopancreatography): Both diagnostic and therapeutic. Allows direct visualization and sampling (brushings, biopsies) of bile duct lesions, and placement of biliary stents for drainage.
EUS (endoscopic ultrasound): Useful for distal CCA and for obtaining tissue via fine-needle aspiration or biopsy.
PET-CT: May help detect distant metastases and lymph node involvement not seen on CT/MRI. Increasingly used in staging evaluation.
A tissue diagnosis is strongly preferred before starting treatment. However, obtaining adequate tissue from bile duct tumors can be challenging.
Biopsy methods: Percutaneous needle biopsy (for intrahepatic tumors), ERCP-guided brushings or biopsies, EUS-guided FNA/biopsy (for distal tumors), or cholangioscopy with targeted biopsies (SpyGlass).
FISH (fluorescence in situ hybridization): Can be performed on biliary brushings to detect polysomy, which increases diagnostic sensitivity.
Molecular profiling (NGS):This is critically important. Comprehensive genomic profiling should be ordered on all CCA tumor tissue. Key targets include FGFR2 fusions/rearrangements, IDH1 mutations, HER2 (IHC 3+), BRAF V600E, NTRK or NRG1 fusions, and MSI-H/dMMR status.
Liquid biopsy (ctDNA): If tissue is insufficient for NGS, blood-based ctDNA testing can identify many of the same actionable targets. Tests like FoundationOne Liquid CDx or Guardant360 CDx are FDA-approved companion diagnostics.
What subtype of cholangiocarcinoma do I have (intrahepatic, perihilar, or distal)?
Has comprehensive molecular profiling (NGS) been ordered on my tumor tissue?
Do I have an FGFR2 fusion, IDH1 mutation, HER2-positive (IHC 3+) status, or any other targetable alteration?
What is my MSI/dMMR status?
Is my tumor resectable, and should I be seen by a hepatobiliary surgeon?
Do I need biliary drainage (stenting), and when should it happen?
Has my case been reviewed by a multidisciplinary tumor board?
If tissue was insufficient for molecular testing, can we do a liquid biopsy?
Key point: Approximately 40–50% of cholangiocarcinomas have a targetable molecular alteration. If your oncologist has not ordered NGS molecular profiling, ask for it. This single test may change your entire treatment plan.
Molecular Profiling — Why Every Mutation Matters
Molecular testing has fundamentally changed CCA treatment. The following are the most important molecular targets in CCA and their corresponding treatments.
FGFR2 fusions occur when the FGFR2 gene fuses with another gene, creating a permanently activated growth signal. These are found almost exclusively in intrahepatic CCA. Multiple FGFR inhibitors are FDA-approved:
Futibatinib (Lytgobi): Oral, irreversible pan-FGFR inhibitor. ORR 42%. May overcome some resistance mutations.
Common side effects of FGFR inhibitors include hyperphosphatemia (high phosphorus levels — managed with diet and phosphate binders), nail changes, dry mouth, hair thinning, dry eyes, and fatigue. A unique side effect is serous retinal detachment — regular eye exams are required.
IDH1 mutations cause the enzyme isocitrate dehydrogenase to produce an abnormal metabolite (2-hydroxyglutarate) that drives cancer growth. The same IDH1 mutations found in some AML leukemia cases also occur in intrahepatic CCA.
Ivosidenib (Tibsovo): An oral IDH1 inhibitor. FDA-approved for previously treated IDH1-mutated CCA based on the ClarIDHy trial. The primary benefit is disease stabilization — many patients have prolonged stable disease rather than tumor shrinkage.
Side effects are generally mild and include fatigue, nausea, diarrhea, and ascites. QTc prolongation requires ECG monitoring.
HER2 (human epidermal growth factor receptor 2) overexpression (IHC 3+) is actionable in biliary tract cancers. It is more common in gallbladder cancer and extrahepatic CCA than in intrahepatic CCA.
Zanidatamab: A bispecific HER2-directed antibody. FDA-approved November 2024 for previously treated HER2-positive (IHC 3+) BTC based on HERIZON-BTC-01 (ORR ~41%).
Trastuzumab deruxtecan (Enhertu): An antibody-drug conjugate approved for other HER2+ cancers; investigated in BTC. The HERB trial showed activity in HER2+ BTC.
BRAF V600E (~3–5% of intrahepatic CCA): Targetable with dabrafenib + trametinib (BRAF + MEK inhibitor combination). The ROAR basket trial showed ORR ~47% in BRAF V600E-mutated BTC. This combination is FDA-approved tumor-agnostically for BRAF V600E mutations.
NTRK fusions (<1% of CCA): Rare but highly actionable. Larotrectinib (Vitrakvi) and entrectinib (Rozlytrek) are FDA-approved tumor-agnostically for NTRK fusion-positive cancers.
MSI-high / dMMR (~2–3% of CCA): Tumors with microsatellite instability-high or deficient mismatch repair respond to pembrolizumab (Keytruda), which is FDA-approved tumor-agnostically for MSI-H/dMMR cancers.
RET fusions (<1%): Targetable with selpercatinib (Retevmo), FDA-approved tumor-agnostically.
NRG1 fusions (<1%): Very rare but now actionable. In May 2026 the FDA approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics), a HER2/HER3 bispecific antibody, on May 8, 2026, for advanced, previously treated cholangiocarcinoma harboring an NRG1 gene fusion — based on the eNRGy trial (NCT02912949). NRG1 fusions are detected only by RNA-based or comprehensive next-generation sequencing, which is one reason thorough molecular profiling matters.
TMB-high: Tumors with high tumor mutational burden may respond to pembrolizumab (FDA-approved tumor-agnostically for TMB ≥10 mutations/Mb).
Key question for your oncologist: “Have you sent my tumor tissue for comprehensive genomic profiling (NGS)? Do I have FGFR2 fusions, IDH1 mutations, HER2-positive (IHC 3+) status, BRAF V600E, NTRK or NRG1 fusions, or MSI-H/dMMR? What are my treatment options based on these results?”
Staging & Subtypes
Staging determines how far the cancer has spread and is critical for deciding treatment. The AJCC 8th Edition staging system is used, and it differs for intrahepatic, perihilar, and distal subtypes.
Stage
Intrahepatic CCA
Perihilar CCA (Bismuth-Corlette)
Distal CCA
Resectable
Tumor confined to liver, no vascular invasion
Types I–II; some Type IIIa/b at experienced centers
Tumor confined to bile duct wall or surrounding tissue
Locally advanced
Major vascular invasion, bilateral liver involvement
Type IV or bilateral vascular involvement
Major vascular involvement
Metastatic
Spread to distant lymph nodes, peritoneum, lungs, bones, or other organs
What is my exact subtype and stage?
Is my tumor resectable? Has a hepatobiliary surgeon reviewed my imaging?
Has my case been discussed at a multidisciplinary tumor board?
Do I have any vascular involvement that would affect resectability?
Are there lymph node or distant metastases?
Should I get a PET-CT for staging?
Surgery — The Only Potentially Curative Treatment
Complete surgical removal (R0 resection — meaning no cancer cells at the margins) offers the best chance of long-term survival. However, only approximately 35% of patients are surgical candidates at diagnosis due to locally advanced or metastatic disease.
Intrahepatic CCA: Hepatectomy (partial liver resection) with lymph node dissection. The extent of liver removal depends on tumor size and location. The liver has remarkable ability to regenerate.
Perihilar CCA: Complex surgery often requiring hepatectomy (right or left) combined with bile duct resection, lymph node dissection, and Roux-en-Y hepaticojejunostomy (reconnecting bile flow to the intestine). Portal vein embolization may be needed before surgery to grow the remaining liver.
Distal CCA: Pancreaticoduodenectomy (Whipple procedure), which removes the head of the pancreas, duodenum, distal bile duct, and gallbladder.
Critical point: These are complex surgeries with significant risks. They should be performed at high-volume hepatobiliary centers where surgeons perform these operations regularly. Surgical volume matters for outcomes.
STANDARD OF CARE The BILCAP trial established capecitabine (Xeloda) for 6 months after surgical resection as the standard adjuvant chemotherapy for biliary tract cancers. In the per-protocol analysis, adjuvant capecitabine improved median overall survival to 51 months vs. 36 months with observation. This is the only adjuvant therapy shown to improve survival in a randomized trial for biliary tract cancers.
At select highly specialized centers, liver transplantation combined with neoadjuvant chemoradiation (the Mayo Protocol) has shown excellent outcomes for unresectable perihilar CCA in carefully selected patients. Reported 5-year survival rates of 65–70% at experienced centers. This protocol involves strict patient selection criteria, neoadjuvant external beam radiation + brachytherapy + capecitabine, followed by staging laparotomy and transplantation. Only a small number of centers offer this approach.
Is my tumor resectable? Who is the hepatobiliary surgeon?
How many of these operations does this surgeon/center perform per year?
What is the plan for achieving clear margins (R0 resection)?
Do I need portal vein embolization to grow my remaining liver before surgery?
Will I receive adjuvant capecitabine after surgery?
Am I a candidate for the liver transplant protocol?
What is the expected recovery time?
First-Line Systemic Treatment
For patients with locally advanced unresectable or metastatic CCA, systemic treatment is the primary approach. The standard has evolved significantly with the addition of immunotherapy.
FDA-APPROVED The TOPAZ-1 trial established the current preferred first-line regimen:
Durvalumab 1500 mg IV every 3 weeks + gemcitabine 1000 mg/m² IV days 1, 8 + cisplatin 25 mg/m² IV days 1, 8 of each 21-day cycle
Chemotherapy given for up to 8 cycles; durvalumab continues until progression
Median OS: 12.8 vs. 11.5 months (HR 0.76); 2-year OS: 24.9% vs. 10.4%
ORR: 26.7% vs. 18.7%
The ABC-02 trial (2010) established gemcitabine + cisplatin as the chemotherapy backbone, showing superior OS compared to gemcitabine alone (11.7 vs. 8.1 months). This remains the backbone to which immunotherapy is now added. For patients who cannot receive immunotherapy, gem/cis alone remains a reasonable option.
When first-line treatment stops working, the approach depends on molecular profiling results:
FGFR2 fusion/rearrangement: Switch to pemigatinib or futibatinib
IDH1 mutation: Switch to ivosidenib
HER2-positive (IHC 3+): Switch to zanidatamab
BRAF V600E: Switch to dabrafenib + trametinib
MSI-H/dMMR: Switch to pembrolizumab
No targetable alteration: Second-line chemotherapy with FOLFOX (5-FU + leucovorin + oxaliplatin) based on the ABC-06 trial, which showed modest but real improvement over supportive care alone
Will I receive durvalumab or pembrolizumab with my chemotherapy?
How many cycles of chemotherapy are planned?
How will we monitor whether the treatment is working?
What are the main side effects, and how will they be managed?
Do I have any targetable mutations for second-line therapy?
When should we re-image to assess response?
Is there a clinical trial I should consider?
Targeted Therapies by Mutation
Targeted therapies are matched to specific molecular alterations in your tumor. They represent one of the most significant advances in CCA treatment. All require molecular profiling (NGS) to identify the target.
Irreversible pan-FGFR inhibitor; may overcome some acquired resistance
Side effects to know about: Hyperphosphatemia is nearly universal — managed with low-phosphorus diet and phosphate binders (sevelamer). Nail changes (onycholysis, paronychia), dry mouth, dry eyes, fatigue, diarrhea. Serous retinal detachment can occur — regular ophthalmologic exams (monthly for the first 6 months, then every 3 months) are mandatory. Most eye changes are reversible with dose modification.
FDA-APPROVED Ivosidenib (Tibsovo) 500 mg PO daily for IDH1-mutated CCA (previously treated).
Median OS: 10.8 vs. 9.7 months (crossover-adjusted HR 0.49)
Disease control rate: ~53%
Primary benefit is disease stabilization rather than tumor shrinkage
Side effects: Generally well-tolerated. Fatigue, nausea, diarrhea, decreased appetite, ascites, QTc prolongation (ECG monitoring required).
FDA-APPROVED Zanidatamab for previously treated HER2-positive (IHC 3+) BTC.
HERIZON-BTC-01 results: ORR ~41%, median DOR ~12.6 months. Zanidatamab binds two different sites on the HER2 receptor simultaneously. Side effects include infusion reactions, diarrhea, and reduced ejection fraction (cardiac monitoring recommended).
Pembrolizumab (Keytruda): For MSI-H/dMMR tumors (any cancer type) or TMB-high (≥10 mut/Mb)
Dabrafenib + trametinib (Tafinlar + Mekinist): For BRAF V600E-mutated tumors (any cancer type). ROAR trial showed ORR ~47% in BRAF V600E BTC.
Larotrectinib (Vitrakvi) or entrectinib (Rozlytrek): For NTRK fusion-positive tumors (any cancer type)
Selpercatinib (Retevmo): For RET fusion-positive tumors (any cancer type)
Why molecular profiling changes everything: Without NGS, a patient with an FGFR2 fusion would receive only standard chemotherapy. With NGS, that same patient gains access to drugs with 36–42% response rates specifically designed for their tumor. The same is true for IDH1, HER2, BRAF, and other targets. This is why every CCA patient should have molecular profiling.
Immunotherapy in Cholangiocarcinoma
Immunotherapy (checkpoint inhibitors) has become an important part of CCA treatment, primarily in the first-line setting.
Checkpoint inhibitors work by removing the “brakes” that cancer cells use to hide from the immune system. In CCA, the combination of immunotherapy with chemotherapy appears to work better than either alone, likely because chemotherapy can make tumor cells more visible to the immune system.
Durvalumab (Imfinzi): Anti-PD-L1 antibody. Used with gem/cis in the TOPAZ-1 regimen.
Pembrolizumab (Keytruda): Anti-PD-1 antibody. Used with gem/cis in the KEYNOTE-966 regimen. Also approved as monotherapy for MSI-H/dMMR tumors.
Immunotherapy can cause inflammation in any organ (immune-related adverse events, or irAEs). The most common include:
Skin rash, itching
Thyroid dysfunction (hypothyroidism or hyperthyroidism)
Colitis (diarrhea, abdominal pain)
Hepatitis (liver inflammation — particularly important in CCA patients who may already have compromised liver function)
Pneumonitis (lung inflammation)
Adrenal insufficiency
Report any new symptoms promptly to your medical team. Most irAEs are manageable if caught early, often with corticosteroids. Severe irAEs may require stopping immunotherapy.
Locoregional Therapies
For intrahepatic CCA that is confined to the liver but not surgically removable, locoregional therapies can be used alongside or after systemic treatment.
Transarterial chemoembolization (TACE): Delivers chemotherapy directly to the tumor through the hepatic artery while blocking blood supply. Used for intrahepatic CCA.
Yttrium-90 radioembolization (SIRT/TARE): Radioactive microspheres delivered through the hepatic artery to irradiate tumor from within. The ABC-07 trial and retrospective data suggest benefit in liver-confined intrahepatic CCA.
Hepatic arterial infusion (HAI) chemotherapy: A pump delivers chemotherapy directly to the liver through the hepatic artery. Primarily available at a small number of specialized centers (notably Memorial Sloan Kettering).
Radiation therapy (SBRT): Stereotactic body radiation therapy can be used for unresectable intrahepatic CCA. Modern techniques (proton therapy, SBRT) can deliver high doses to the tumor while sparing surrounding liver.
Ablation (RFA/microwave): Can be used for small, liver-confined intrahepatic CCA (<3 cm) when surgery is not feasible.
Many CCA patients require biliary drainage to relieve bile duct obstruction. This is not cancer treatment but is essential for managing symptoms and allowing chemotherapy to proceed safely.
ERCP with stenting: An endoscope is used to place a plastic or metal stent inside the blocked bile duct. Most common approach for perihilar and distal CCA.
Percutaneous transhepatic biliary drainage (PTBD): An external or internal-external drain is placed through the skin into the bile duct. Used when ERCP is not feasible or fails.
Metal vs. plastic stents: Self-expanding metal stents (SEMS) last longer but are not removable. Plastic stents can be exchanged but clog more frequently (every 3 months).
Cholangitis warning: If you develop fever, chills, and worsening jaundice after stent placement, this may indicate cholangitis (bile duct infection) and requires urgent medical attention.
Based on my molecular profiling, am I eligible for any targeted therapies?
Is there a locoregional therapy option for my liver-confined disease?
Should I be seen at a center that offers hepatic arterial infusion (HAI) chemotherapy?
How will my biliary drainage be managed long-term?
Are there clinical trials for my molecular subtype?
What happens when my current treatment stops working?
Supportive Care
Supportive care is a critical component of CCA management, addressing the symptoms and complications that affect quality of life.
Biliary drainage (as described above) is the primary treatment for obstructive jaundice.
Pruritus (itching): Can be severe and debilitating. Treatments include cholestyramine (bile acid sequestrant), rifampin, naltrexone, sertraline, and gabapentin. Ursodeoxycholic acid (UDCA) may help. Keep skin moisturized. Avoid hot showers. Cool compresses can provide temporary relief.
Biliary obstruction impairs fat digestion. You may need pancreatic enzyme supplements (lipase) with meals.
Fat-soluble vitamin deficiencies (A, D, E, K) are common. Supplementation may be needed, especially vitamin K for coagulation.
Work with a registered dietitian experienced in hepatobiliary cancer. Small, frequent meals are often better tolerated.
Weight loss is common. Nutritional supplements and appetite stimulants may be considered.
Pain from CCA can be significant, particularly with liver capsule involvement or nerve invasion.
A multimodal approach including acetaminophen, NSAIDs (with caution in liver disease), opioids, and adjuvant medications (gabapentin, pregabalin) may be needed.
Celiac plexus neurolysis: A nerve block procedure that can provide significant pain relief for tumor-related abdominal pain.
Early palliative care consultation improves quality of life and should not be viewed as “giving up.”
Pregnancy, Fertility & Family Planning
Bile duct cancer is most common after age 50, but it does occur in younger adults — particularly with predisposing conditions such as primary sclerosing cholangitis, choledochal cysts, or liver-fluke infection. If you are of childbearing age, these are important conversations to have before treatment begins.
⚠ The drugs used for bile duct cancer can seriously harm a developing baby. Chemotherapy (gemcitabine, cisplatin), the targeted FGFR inhibitors (pemigatinib, futibatinib), the IDH1 inhibitor (ivosidenib), the HER2 antibody (zanidatamab), and the immunotherapies (durvalumab, pembrolizumab) are all expected to cause fetal harm or pregnancy loss. If you can become pregnant, confirm a negative pregnancy test before starting and use effective contraception during treatment and for the period after the last dose specified for each drug. Men with partners who can become pregnant should also ask about contraception.
Fertility preservation: ask for a referral to a reproductive specialist before chemotherapy or targeted therapy starts — options include egg, sperm, or embryo freezing. Treatment can reduce future fertility.
The FGFR inhibitors (pemigatinib, futibatinib) deserve special note: the FGF/FGFR pathway is essential to fetal development, so these drugs are particularly likely to cause harm in pregnancy. They also commonly raise blood phosphate and can affect the eyes, which your team monitors.
If you are already pregnant at diagnosis, care is individualized by a team including your oncologist and a maternal-fetal-medicine specialist; some surgery and certain chemotherapy may be possible in later pregnancy, but most targeted and immunotherapy drugs are avoided.
Breastfeeding is not recommended during these treatments and for a period afterward.
Questions to ask your team: Could this treatment affect my ability to have children, and should I see a fertility specialist first? Which of my medicines are unsafe in pregnancy, and what contraception do you recommend and for how long? If I am or become pregnant, what are my options?
class="content-section" data-stage="advanced">
Clinical Trials — Finding and Enrolling
Clinical trials are particularly important in CCA because the disease is rare and new therapies are being developed rapidly. Trials offer access to potentially superior treatments before they are widely available.
ESMO (Europe): Clinical Practice Guidelines for biliary tract cancers
ASCO (US): Biliary tract cancer guidelines
NICE (UK): Individual technology appraisals for CCA drugs
JSBT (Japan): Japanese Society of Biliary Tract research guidelines
Health Canada / CADTH: Canadian access pathway for biliary tract cancer drugs
Failed & De-Adopted Therapies
Knowing what has not worked is as important as knowing what has. These therapies were tested in CCA and either failed or have been supplanted by better options.
WITHDRAWN Infigratinib was approved by the FDA in May 2021 for previously treated FGFR2 fusion/rearrangement CCA. The manufacturer (QED Therapeutics/Helsinn) voluntarily withdrew the drug from the US market in 2024 due to commercial factors, not safety or efficacy concerns. The confirmatory PROOF 301 trial was terminated. Pemigatinib and futibatinib remain available alternatives.
FAILED Multiple studies investigated adding erlotinib (an EGFR inhibitor) to gemcitabine for biliary tract cancers. No randomized trial demonstrated a clear survival benefit. EGFR inhibitors as a class have not shown consistent efficacy in unselected BTC populations.
FAILED Selumetinib and other MEK inhibitors were tested in unselected BTC populations. The ABC-04 trial showed insufficient activity to warrant further development in unselected patients. The lesson: molecularly unselected BTC trials have largely failed, reinforcing the importance of biomarker-driven treatment.
FAILED The SWOG S1815 trial tested the addition of nab-paclitaxel to gemcitabine/cisplatin in first-line advanced BTC. The triplet did not improve overall survival compared to gemcitabine/cisplatin alone, and caused more toxicity. This approach should not be used.
Why this matters: If someone suggests one of these therapies, you now know its history. Always ask: “Has this been tested in a randomized trial for cholangiocarcinoma, and what were the results?”
class="content-section" data-stage="resources">
Specialty Centers
CCA outcomes improve when care is coordinated by a multidisciplinary team at a center with hepatobiliary expertise. High-volume surgical centers have lower complication rates and better outcomes. A second opinion at a specialized center is strongly recommended.
No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.
Huntsman Cancer Institute (HCI) — University of Utah
NCI-designated Comprehensive Cancer Center with hepatobiliary surgery and GI oncology programs
Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112 Phone: 801-585-0303 Programs: Hepatobiliary Surgery Program, GI Medical Oncology, Interventional Radiology, active clinical trials for biliary tract cancers. Multidisciplinary hepatobiliary tumor board. Molecular profiling through ARUP Laboratories.
Why it matters. HCI is the only NCI-designated Comprehensive Cancer Center in the Mountain West region. Its hepatobiliary program offers complex liver resections, biliary reconstruction, and access to molecularly targeted trials for CCA.
Location: Phoenix, AZ Phone: 480-301-8000 Programs: Hepatobiliary surgery, liver transplantation, GI oncology, clinical trials.
How to choose. For CCA in the Mountain West, Huntsman Cancer Institute offers the most comprehensive hepatobiliary cancer program including NCI trial access. Intermountain Health provides broad community-based oncology coverage. For complex surgical cases, ensure the operating surgeon has high-volume hepatobiliary experience.
Information verified May 2026. Availability changes — confirm with each institution directly.
Memorial Sloan Kettering Cancer Center
Location: New York, NY · Phone: 212-639-2000
World-leading hepatobiliary surgery program. Hepatic arterial infusion (HAI) chemotherapy program — one of the few centers offering this. Extensive BTC clinical trial portfolio. Molecular profiling through MSK-IMPACT.
MD Anderson Cancer Center
Location: Houston, TX · Phone: 877-632-6789
Large hepatobiliary program with dedicated BTC clinical trials team. FGFR inhibitor and immunotherapy combination trials. High-volume hepatobiliary surgery.
Mayo Clinic Rochester
Location: Rochester, MN · Phone: 507-538-3270
Pioneered the liver transplant protocol for perihilar CCA (Mayo Protocol). Hepatobiliary surgery, GI oncology, clinical trials.
Johns Hopkins Sidney Kimmel Cancer Center
Location: Baltimore, MD · Phone: 410-955-5000
High-volume hepatobiliary surgery. Pancreaticoduodenectomy (Whipple) for distal CCA. GI oncology trials.
Massachusetts General Hospital / Dana-Farber
Location: Boston, MA · Phone: 617-726-2000 (MGH) / 617-632-3000 (DFCI)
Hepatobiliary surgery program, GI oncology, biliary tract cancer-specific trials.
VA Salt Lake City Health Care System (George E. Wahlen VAMC)
Phone: 801-582-1565
Hematology/oncology and gastroenterology services. Partnership with Huntsman Cancer Institute for surgical and clinical trial access. Veterans may access hepatobiliary surgical care through VA Community Care referral to HCI or other academic centers.
VA Cancer Care
Website:cancer.va.gov VA Community Care: 1-877-881-7618
Complex hepatobiliary cases, including CCA, can be referred to academic surgical centers through VA Community Care.
Princess Margaret Cancer Centre (UHN), Toronto
Phone: 416-946-4501
GI oncology program with hepatobiliary expertise. Clinical trials for biliary tract cancers through CCTG.
McGill University Health Centre, Montreal
Phone: 514-934-1934
Hepatobiliary surgery and GI oncology.
Canadian Cancer Society helpline: 1-888-939-3333
International Centers of Excellence for CCA
King’s College Hospital, London, UK: Major hepatobiliary and liver transplant center. UK lead for ABC trials (ABC-02, ABC-06, ABC-07).
Beaujon Hospital (APHP), Paris, France: European center of expertise for biliary tract cancers.
National Cancer Center Hospital, Tokyo, Japan: Leading Asian center for BTC research and clinical trials.
Asan Medical Center, Seoul, South Korea: High-volume hepatobiliary surgery with global leadership in BTC outcomes research.
Khon Kaen University, Thailand: World leader in liver fluke-associated CCA research and treatment.
Caregiver Guidance
Caring for someone with CCA involves managing complex medical logistics, emotional challenges, and practical needs. Here is what caregivers need to know.
Keep a medical binder. Track medications, lab results, imaging dates, stent changes, and questions for the team. CCA care involves many specialists — having everything in one place is essential.
Know the warning signs. Fever, worsening jaundice, dark urine, pale stools, or severe abdominal pain may indicate cholangitis (bile duct infection) or stent blockage. These are urgent — go to the emergency department.
Support nutrition. Bile duct cancer affects digestion. Work with a dietitian. Prepare small, frequent, low-fat meals. Give pancreatic enzymes with meals as directed.
Manage the itch. Pruritus from biliary obstruction can be maddening. Help implement anti-itch strategies: cool compresses, moisturizers, oatmeal baths, and prescribed medications.
Cholangiocarcinoma Foundation:cholangiocarcinoma.org — Dedicated support community, educational resources, and annual conference for patients and caregivers.
Seek professional support: social workers, psychologists, and chaplains at your cancer center.
Caregiver burnout is real. Accept help, take breaks, and maintain your own health. You cannot pour from an empty cup.
Advance care planning conversations are important. Have them when the patient is well enough to participate.
Glossary
Adjuvant therapy
Treatment given after surgery to reduce the risk of cancer returning. In CCA, this is typically capecitabine for 6 months.
Bile duct
Tubes that carry bile from the liver to the small intestine. Cholangiocarcinoma arises from the lining of these ducts.
Biliary drainage
Procedure to relieve blockage of the bile ducts, usually by placing a stent via ERCP or percutaneous approach.
Bismuth-Corlette classification
A system for classifying perihilar CCA by location relative to the bile duct junction. Types I-IV, with higher types being more extensive.
BRAF V600E
A specific mutation in the BRAF gene found in ~3-5% of intrahepatic CCA. Targetable with dabrafenib + trametinib.
CA 19-9
A tumor marker often elevated in cholangiocarcinoma. Used for monitoring treatment response but not specific to CCA.
Capecitabine
An oral chemotherapy (brand name Xeloda) used as adjuvant therapy after CCA surgery (BILCAP trial).
Cholangitis
Infection of the bile duct. A potentially life-threatening emergency that requires urgent antibiotics and biliary drainage.
ctDNA
Circulating tumor DNA. Fragments of tumor DNA found in the blood that can be tested for molecular targets (liquid biopsy).
dMMR
Deficient mismatch repair. A DNA repair defect that makes tumors respond well to immunotherapy (pembrolizumab).
ERCP
Endoscopic retrograde cholangiopancreatography. A procedure using an endoscope to access the bile ducts for diagnosis, stenting, and biopsy.
FGFR2 fusion
A genetic alteration where the FGFR2 gene joins with another gene, creating an abnormal growth signal. Found in ~10-15% of intrahepatic CCA. Targetable with pemigatinib or futibatinib.
Gemcitabine/cisplatin
The standard chemotherapy backbone for advanced CCA, now combined with durvalumab or pembrolizumab.
HER2
Human epidermal growth factor receptor 2. When HER2-positive (IHC 3+), targetable with zanidatamab in BTC.
IDH1
Isocitrate dehydrogenase 1. Mutated in ~13-20% of intrahepatic CCA. Targetable with ivosidenib.
Intrahepatic CCA
Cholangiocarcinoma arising within the liver. The subtype most likely to harbor FGFR2 and IDH1 alterations.
Jaundice
Yellowing of the skin and eyes caused by elevated bilirubin, often from bile duct obstruction.
Klatskin tumor
Another name for perihilar cholangiocarcinoma, named after Dr. Gerald Klatskin.
MSI-H
Microsatellite instability-high. A molecular feature that predicts response to immunotherapy.
NGS
Next-generation sequencing. Comprehensive molecular profiling of tumor DNA to identify targetable mutations. Essential for all CCA patients.
Perihilar CCA
Cholangiocarcinoma at the junction where right and left bile ducts meet. The most common CCA subtype.
PSC
Primary sclerosing cholangitis. A chronic inflammatory bile duct disease that increases CCA risk.
R0 resection
Surgical removal with no cancer cells at the margins. The goal of curative surgery in CCA.
TACE
Transarterial chemoembolization. A procedure delivering chemotherapy directly to liver tumors through the hepatic artery.
Whipple procedure
Pancreaticoduodenectomy. Surgery to remove the head of the pancreas, duodenum, and distal bile duct. Used for distal CCA.
Sources and Further Reading
This guide draws on published medical literature, clinical trial records, and the work of physicians treating cholangiocarcinoma across multiple countries. Key sources are listed below.
TOPAZ-1: Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8). (NCT03875235)
KEYNOTE-966: Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966). Lancet. 2023;401(10391):1853–1865. (NCT04003636)
ABC-02: Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
ABC-06: Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06). Lancet Oncol. 2021;22(5):690–701.
BILCAP: Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP). Lancet Oncol. 2019;20(5):663–673.
FIGHT-202: Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684. (NCT02924376)
FOENIX-CCA2: Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–239. (NCT02052778)
ClarIDHy: Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669–1677. (NCT02989857)
Zenocutuzumab-zbco (Bizengri): FDA accelerated approval for NRG1-fusion cholangiocarcinoma, May 2026 (eNRGy trial).
External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.
What This Guide Does Not Know
An honest guide names its own limits:
This guide cannot diagnose, stage, or treat anyone. It does not know your subtype, molecular profile, liver function, or personal preferences. Only your medical team can build an actual plan.
CCA treatment is changing rapidly. New molecular targets, combination strategies, and trial results emerge frequently. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual outcomes cannot be predicted. The same molecular subtype can behave differently in different patients. Statistics describe populations, not individuals.
Rare cancers require specialized care. CCA is uncommon, and not all oncologists see enough cases to stay current with the rapidly evolving treatment landscape. Referral to a hepatobiliary center for at least a second opinion is often the single highest-value step a patient can take.
A final word. Cholangiocarcinoma is a challenging diagnosis. The rarity of the disease, the complexity of treatment, and the often late-stage diagnosis can feel isolating and overwhelming. But the CCA treatment landscape has genuinely transformed. Immunotherapy combinations have become standard first-line therapy. Multiple targeted drugs now exist for specific molecular subtypes. Clinical trials are testing even more promising approaches. Get your molecular profiling. Get to a hepatobiliary center. Ask about trials. Connect with the Cholangiocarcinoma Foundation. You are not alone. Help is real. Use it.
Important Drug Safety Warnings
Cholangiocarcinoma (bile duct cancer) is treated with chemotherapy and, in FGFR2-fusion or IDH1/IDH2-mutant tumors, targeted therapies. Each has important safety considerations.
Hyperphosphatemia (dangerously high phosphate levels): FGFR inhibitors block normal phosphate excretion by the kidneys, causing phosphate to accumulate in the blood. Severe, uncontrolled hyperphosphatemia can cause calcification of blood vessels, organs, and soft tissues. This is the most serious manageable complication of FGFR inhibitor therapy. You will need a low-phosphate diet (avoiding dairy, nuts, processed foods, colas) and may be prescribed phosphate-binding medications. Phosphate levels are monitored at every clinic visit. Report fatigue, itching, or muscle cramps (early signs of high phosphate).
Eye toxicity (retinal pigment epithelial detachment): FGFR inhibitors can cause serious eye problems including retinal pigment epithelial detachment (RPED), which can cause blurred or distorted vision. Ophthalmologic examination (dilated eye exam) is required before starting and regularly during therapy. Report any new visual disturbances, floaters, or reduced vision immediately.
Nail and skin toxicity: Nail changes (nail bed changes, paronychia/nail fold infections) and skin reactions are common. Maintain good nail hygiene; report painful nail changes to your oncology team for management.
Dry mouth, dry eyes: Mucositis, dry eyes, and dry skin are frequent. Regular moisturizing eye drops (preservative-free artificial tears) and good oral hygiene help manage these effects.
Pregnancy — do not use: FGFR inhibitors can cause serious fetal harm. Women of childbearing potential must use effective contraception during therapy and for at least 1 week (pemigatinib) after the final dose. Do not breastfeed during or after therapy.
QT prolongation: Ivosidenib can prolong the QT interval (electrical signal in the heart), increasing the risk of serious heart rhythm problems. ECG monitoring before and during treatment is required. Avoid other QT-prolonging medications (discuss with your oncologist before taking any new drug). Report palpitations, dizziness, or fainting immediately.
Drug interactions: Ivosidenib is metabolized by the CYP3A4 liver enzyme. Many common medications (azole antifungals, certain antibiotics, rifampin, some antiepileptics) can significantly increase or decrease its levels. Always tell your oncologist about all medications, supplements, and herbal products before starting.
Gemcitabine + cisplatin chemotherapy:
Myelosuppression: This combination suppresses the bone marrow, reducing red blood cells (anemia), white cells (neutropenia, increasing infection risk), and platelets (thrombocytopenia, increasing bleeding risk). You will have blood counts checked before each cycle. Report fever ≥38°C (100.4°F) immediately — this is a neutropenic fever and requires urgent evaluation.
Kidney protection (cisplatin): Cisplatin is toxic to the kidneys. IV hydration before and after each cisplatin infusion is required. Avoid NSAIDs and dehydration during treatment. Tell your team about any decrease in urine output.
Nausea and neuropathy: Cisplatin causes significant nausea (anti-nausea medications are given with each infusion) and can cause peripheral neuropathy (numbness, tingling in hands and feet) that may be lasting.